glp-1 dual agonist GIPR/GLP-1R therapies for diabetes and weight loss– Chemistry, Physiology and Clinical application Curious about the latest in
Description
The results of the phase 3 trial were published on Wednesday, Sept
They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk
Most are administered via subcutaneous injection, with dosing frequencies ranging from twice daily to once weekly depending on the specific formulation
Make sure your insurance will approve the medication if your doctor prescribes a GLP-1 agonist
